Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Transl Med ; 12(543)2020 05 13.
Article in English | MEDLINE | ID: mdl-32404505

ABSTRACT

We aimed to develop effective radioligands for quantifying brain O-linked-ß-N-acetyl-glucosamine (O-GlcNAc) hydrolase (OGA) using positron emission tomography in living subjects as tools for evaluating drug target engagement. Posttranslational modifications of tau, a biomarker of Alzheimer's disease, by O-GlcNAc through the enzyme pair OGA and O-GlcNAc transferase (OGT) are inversely related to the amounts of its insoluble hyperphosphorylated form. Increase in tau O-GlcNAcylation by OGA inhibition is believed to reduce tau aggregation. LSN3316612, a highly selective and potent OGA ligand [half-maximal inhibitory concentration (IC50) = 1.9 nM], emerged as a lead ligand after in silico analysis and in vitro evaluations. [3H]LSN3316612 imaged and quantified OGA in postmortem brains of rat, monkey, and human. The presence of fluorine and carbonyl functionality in LSN3316612 enabled labeling with positron-emitting fluorine-18 or carbon-11. Both [18F]LSN3316612 and [11C]LSN3316612 bound reversibly to OGA in vivo, and such binding was blocked by pharmacological doses of thiamet G, an OGA inhibitor of different chemotype, in monkeys. [18F]LSN3316612 entered healthy human brain avidly (~4 SUV) without radiodefluorination or adverse effect from other radiometabolites, as evidenced by stable brain total volume of distribution (VT) values by 110 min of scanning. Overall, [18F]LSN3316612 is preferred over [11C]LSN3316612 for future human studies, whereas either may be an effective positron emission tomography radioligand for quantifying brain OGA in rodent and monkey.


Subject(s)
Hydrolases , beta-N-Acetylhexosaminidases , Animals , Brain/diagnostic imaging , Brain/metabolism , Glucosamine , Ligands , Positron-Emission Tomography , Rats , beta-N-Acetylhexosaminidases/metabolism
2.
Front Neurosci ; 13: 735, 2019.
Article in English | MEDLINE | ID: mdl-31396031

ABSTRACT

Dynamic gain and loss of synapses is fundamental to healthy brain function. While Alzheimer's Disease (AD) treatment strategies have largely focussed on beta-amyloid and tau protein pathologies, the synapse itself may also be a critical endpoint to consider regarding disease modification. Disruption of mechanisms of neuronal plasticity, eventually resulting in a net loss of synapses, is implicated as an early pathological event in AD. Synaptic dysfunction therefore may be a final common biological mechanism linking protein pathologies to disease symptoms. This review summarizes evidence supporting the idea of early neuroplastic deficits being prevalent in AD. Changes in synaptic density can occur before overt neurodegeneration and should not be considered to uniformly decrease over the course of the disease. Instead, synaptic levels are influenced by an interplay between processes of degeneration and atrophy, and those of maintenance and compensation at regional and network levels. How these neuroplastic changes are driven by amyloid and tau pathology are varied. A mixture of direct effects of amyloid and tau on synaptic integrity, as well as indirect effects on processes such as inflammation and neuronal energetics are likely to be at play here. Focussing on the synapse and mechanisms of neuroplasticity as therapeutic opportunities in AD raises some important conceptual and strategic issues regarding translational research, and how preclinical research can inform clinical studies. Nevertheless, substrates of neuroplasticity represent an emerging complementary class of drug target that would aim to normalize synapse dynamics and restore cognitive function in the AD brain and in other neurodegenerative diseases.

3.
J Med Chem ; 59(23): 10800-10806, 2016 12 08.
Article in English | MEDLINE | ID: mdl-27933953

ABSTRACT

1,4-Benzodiazepines are used in the treatment of anxiety disorders but have limited long-term use due to adverse effects. HZ-166 (2) has been shown to have anxiolytic-like effects with reduced sedative/ataxic liabilities. A 1,3-oxazole KRM-II-81 (9) was discovered from a series of six bioisosteres with significantly improved pharmacokinetic and pharmacodynamic properties as compared to 2. Oxazole 9 was further characterized and exhibited improved anxiolytic-like effects in a mouse marble burying assay and a rat Vogel conflict test.


Subject(s)
Anti-Anxiety Agents/pharmacology , Benzodiazepines/pharmacology , GABA-A Receptor Antagonists/pharmacology , Imidazoles/pharmacology , Oxazoles/pharmacology , Receptors, GABA-A/metabolism , Animals , Anti-Anxiety Agents/chemistry , Anti-Anxiety Agents/metabolism , Anxiety/drug therapy , Benzodiazepines/chemistry , Benzodiazepines/metabolism , Dose-Response Relationship, Drug , Epilepsy/drug therapy , GABA-A Receptor Antagonists/chemistry , GABA-A Receptor Antagonists/metabolism , HEK293 Cells , Humans , Imidazoles/chemistry , Imidazoles/metabolism , Ligands , Male , Mice , Mice, Inbred Strains , Molecular Structure , Oxazoles/chemistry , Oxazoles/metabolism , Pain/drug therapy , Rats , Rats, Sprague-Dawley , Structure-Activity Relationship
4.
J Biomol Screen ; 21(5): 468-79, 2016 Jun.
Article in English | MEDLINE | ID: mdl-26838761

ABSTRACT

N-methyl-D-aspartate receptors (NMDARs) are ionotropic glutamate receptors that play an important role in synaptic plasticity and learning and memory formation. Malfunctioning of NMDARs, in particular the reduction in NMDAR activity, is thought to be implicated in major neurological disorders. NMDAR positive allosteric modulators (PAMs) represent potential therapeutic interventions for restoring normal NMDAR function. We report a novel screening approach for identification and characterization of NMDAR-PAMs. The approach combines high-throughput fluorescence imaging with automated electrophysiological recording of glutamate-evoked responses in HEK-293 cells expressing NR1/NR2A NMDAR subunits. Initial high-throughput screening (HTS) of a chemical library containing >810,000 compounds using a calcium flux assay in 1536-well plate format identified a total of 864 NMDAR-PAMs. Concentration response determination in both calcium flux and automated electrophysiological assays found several novel chemical series with EC50 values between 0.49 and 10 µM. A small subset (six series) was selected and analyzed for pharmacological properties, subtype selectivity, mode of action, and activity at native NMDARs. Our approach demonstrates the successful application of HTS functional assays that led to identification of NMDAR-PAMs providing the foundation for further medicinal chemistry work that may lead to novel therapies for treatment of cognitive impairment associated with Alzheimer's disease and schizophrenia.


Subject(s)
Drug Discovery/methods , High-Throughput Screening Assays/methods , Receptors, N-Methyl-D-Aspartate/metabolism , Small Molecule Libraries/isolation & purification , Allosteric Regulation/drug effects , Alzheimer Disease/drug therapy , Calcium/chemistry , Glutamic Acid/chemistry , Glutamic Acid/metabolism , HEK293 Cells , Humans , Neuronal Plasticity/drug effects , Receptors, N-Methyl-D-Aspartate/drug effects , Schizophrenia/drug therapy , Small Molecule Libraries/chemistry , Small Molecule Libraries/pharmacology
5.
Mol Cancer Ther ; 13(2): 364-74, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24356814

ABSTRACT

p38α mitogen-activated protein kinase (MAPK) is activated in cancer cells in response to environmental factors, oncogenic stress, radiation, and chemotherapy. p38α MAPK phosphorylates a number of substrates, including MAPKAP-K2 (MK2), and regulates the production of cytokines in the tumor microenvironment, such as TNF-α, interleukin-1ß (IL-1ß), IL-6, and CXCL8 (IL-8). p38α MAPK is highly expressed in human cancers and may play a role in tumor growth, invasion, metastasis, and drug resistance. LY2228820 dimesylate (hereafter LY2228820), a trisubstituted imidazole derivative, is a potent and selective, ATP-competitive inhibitor of the α- and ß-isoforms of p38 MAPK in vitro (IC(50) = 5.3 and 3.2 nmol/L, respectively). In cell-based assays, LY2228820 potently and selectively inhibited phosphorylation of MK2 (Thr334) in anisomycin-stimulated HeLa cells (at 9.8 nmol/L by Western blot analysis) and anisomycin-induced mouse RAW264.7 macrophages (IC(50) = 35.3 nmol/L) with no changes in phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc ≤ 10 µmol/L. LY2228820 also reduced TNF-α secretion by lipopolysaccharide/IFN-γ-stimulated macrophages (IC(50) = 6.3 nmol/L). In mice transplanted with B16-F10 melanoma, tumor phospho-MK2 (p-MK2) was inhibited by LY2228820 in a dose-dependent manner [threshold effective dose (TED)(70) = 11.2 mg/kg]. Significant target inhibition (>40% reduction in p-MK2) was maintained for 4 to 8 hours following a single 10 mg/kg oral dose. LY2228820 produced significant tumor growth delay in multiple in vivo cancer models (melanoma, non-small cell lung cancer, ovarian, glioma, myeloma, breast). In summary, LY2228820 is a p38 MAPK inhibitor, which has been optimized for potency, selectivity, drug-like properties (such as oral bioavailability), and efficacy in animal models of human cancer.


Subject(s)
Imidazoles/pharmacology , Neoplasms/drug therapy , Pyridines/pharmacology , Xenograft Model Antitumor Assays , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors , Adenosine Triphosphate/metabolism , Animals , Anisomycin/pharmacology , Binding Sites , Blotting, Western , Cell Line , Cell Line, Tumor , Cells, Cultured , Cytokines/metabolism , Dose-Response Relationship, Drug , HeLa Cells , Humans , Imidazoles/chemistry , Macrophages/drug effects , Macrophages/metabolism , Melanoma, Experimental/drug therapy , Melanoma, Experimental/pathology , Mice , Molecular Structure , Neoplasms/genetics , Neoplasms/metabolism , Phosphorylation/drug effects , Pyridines/chemistry , RNA Interference , Treatment Outcome , p38 Mitogen-Activated Protein Kinases/genetics , p38 Mitogen-Activated Protein Kinases/metabolism
6.
Bioorg Med Chem Lett ; 18(1): 179-83, 2008 Jan 01.
Article in English | MEDLINE | ID: mdl-18039577

ABSTRACT

Herein we report investigations into the p38alpha MAP kinase activity of trisubstituted imidazoles that led to the identification of compounds possessing highly potent in vivo activity. The SAR of a novel series of imidazopyridines is demonstrated as well, resulting in compounds possessing cellular potency and enhanced in vivo activity in the rat collagen-induced arthritis model of chronic inflammation.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Imidazoles/pharmacology , Mitogen-Activated Protein Kinase 14/antagonists & inhibitors , Pyridines/pharmacology , Adenosine Triphosphate/analogs & derivatives , Adenosine Triphosphate/metabolism , Animals , Anti-Inflammatory Agents/chemistry , Anti-Inflammatory Agents/pharmacokinetics , Benzimidazoles/chemistry , Benzimidazoles/pharmacokinetics , Benzimidazoles/pharmacology , Edema/drug therapy , ErbB Receptors/metabolism , Humans , Imidazoles/chemistry , Imidazoles/pharmacokinetics , Mice , Mice, Inbred BALB C , Peptide Fragments/metabolism , Pyridines/chemistry , Pyridines/pharmacokinetics , Rats , Structure-Activity Relationship , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/metabolism
7.
J Biol Chem ; 278(16): 14134-45, 2003 Apr 18.
Article in English | MEDLINE | ID: mdl-12571238

ABSTRACT

We address the specific role of cytoplasmic Ca(2+) overload as a cell death trigger by expressing a receptor-operated specific Ca(2+) channel, vanilloid receptor subtype 1 (VR1), in Jurkat cells. Ca(2+) uptake through the VR1 channel, but not capacitative Ca(2+) influx stimulated by the muscarinic type 1 receptor, induced sustained intracellular [Ca(2+)] rises, exposure of phosphatidylserine, and cell death. Ca(2+) influx was necessary and sufficient to induce mitochondrial damage, as assessed by opening of the permeability transition pore and collapse of the mitochondrial membrane potential. Ca(2+)-induced cell death was inhibited by ruthenium red, protonophore carbonyl cyanide m-chlorophenylhydrazone, or cyclosporin A treatment, as well as by Bcl-2 expression, indicating that this process requires mitochondrial calcium uptake and permeability transition pore opening. Cell death occurred without caspase activation, oligonucleosomal/50-kilobase pair DNA cleavage, or release of cytochrome c or apoptosis inducer factor from mitochondria, but it required oxidative/nitrative stress. Thus, Ca(2+) influx triggers a distinct program of mitochondrial dysfunction leading to paraptotic cell death, which does not fulfill the criteria for either apoptosis or necrosis.


Subject(s)
Calcium/metabolism , Mitochondria/metabolism , Animals , Apoptosis , Calcium Channels/metabolism , Carbonyl Cyanide m-Chlorophenyl Hydrazone/pharmacology , Caspases/metabolism , Cell Line , Coloring Agents/pharmacology , Cyclosporine/pharmacology , Cytochrome c Group/metabolism , DNA/metabolism , DNA Fragmentation , Enzyme Activation , Green Fluorescent Proteins , Humans , In Situ Nick-End Labeling , Ionophores/pharmacology , Jurkat Cells , Kinetics , Luminescent Proteins/metabolism , Membrane Potentials , Microscopy, Fluorescence , Nitrogen/metabolism , Oxidative Stress , Protein Structure, Tertiary , Proto-Oncogene Proteins c-bcl-2/metabolism , Rats , Reactive Nitrogen Species , Reactive Oxygen Species , Ruthenium Red/pharmacology , T-Lymphocytes/metabolism , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL